This article is more than 5 years old. Information may no longer be current.

Independent testing verifies the accuracy of brachytherapy dose delivery

Med Phys. 2009;36(10):4370-4378.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The accuracy of radiation brachytherapy delivery, which may be used to treat patients with age-related macular degeneration, has been independently verified, and the delivery system meets requirements for accuracy established by the Nuclear Regulatory Commission, according to a study.

Researchers sought to quantify the accuracy of the Vidion anti-neovascular therapy system (NeoVista). In the study, the well chamber delivered ionization current through a reference cannula with a variation in the signal between ±0.3% and ±0.5%.

Testing of single use cannulae demonstrated a signal that was an average of 17.8% ± 0.4% of the reference signal. "Measurements presented here also validate the source deployment verification acceptance range," the study authors said.

"Cannula-to-cannula variations for either reference or clinical cannulae were within an acceptable range (less than 1%), except for a single outlying reference cannula that is currently undergoing testing by NeoVista to determine the physical cause of the increased signal," they said.